A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis
Status:
Completed
Trial end date:
2021-05-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate, in participants having achieved a state of
sustained remission, if the ixekizumab treatment groups are superior to the placebo group in
maintaining response during the randomized withdrawal-retreatment period in participants with
axial spondyloarthritis.